Effectiveness of traditional Vietnamese medicine Kovir capsule in adults with mild <scp>COVID</scp>‐19: A propensity score‐matched study

Loc, Huynh Nguyen; Lan, Truong Thi Ngoc; Huong, Dinh Thi Lan; Tuyen, Nguyen Thanh; Quang, Tran; Dao, Ly Minh; Vuong, Nguyen Lam

doi:10.1002/ptr.7668

Cited by 2 publications

(3 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous studies on Kovir (Loc, Lan, Huong, Tuyen, Quang, Dao, Van, et al, 2022a; Loc, Lan, Huong, Tuyen, Quang, Dao, & Vuong, 2022b) were performed when the delta variant was the dominant cause of infections in our country. This study was conducted while the omicron variant was spreading in our country and all over the world.…”

Section: Discussionmentioning

confidence: 94%

“…Previously, in a phase II trial (Loc, Lan, Huong, Tuyen, Quang, Dao, Van, et al, 2022a) and a non‐randomized study (Loc, Lan, Huong, Tuyen, Quang, Dao, & Vuong, 2022b), oral Kovir capsule (TD0019) has shown the safety and potential efficacy in terms of symptom resolution and prevention of progression to severe diseases for mild COVID‐19 patients. However, these studies were conducted in the era of the delta variant, and the evidence needs to be strengthened by larger trials.…”

Section: Introductionmentioning

confidence: 99%

“…Previously, in a phase II trial (Loc, Lan, Huong, Tuyen, Quang, Dao, Van, et al, 2022a) and a non-randomized study (Loc, Lan, Huong, Tuyen, Quang, Dao, & Vuong, 2022b), oral Kovir capsule (TD0019)…”

mentioning

confidence: 99%

See 2 more Smart Citations

Traditional Vietnamese medicine Kovir capsule for non‐severe COVID‐19 patients: A phase III double‐blind randomized controlled trial

Loc¹,

Hoan²,

Vuong

et al. 2023

Phytotherapy Research

Self Cite

View full text Add to dashboard Cite

The number of COVID‐19 infections is still increasing with the omicron variant. Although vaccination has shown its effectiveness, efficacious treatments are still required. Kovir, a Vietnamese herbal medicine, has shown potential effects for non‐severe COVID‐19 patients in terms of symptom resolution and prevention of disease progression in previous studies. This phase‐3 trial evaluated the safety and efficacy of Kovir for non‐severe COVID‐19 adults. Participants were randomized to the Kovir (381 patients) or placebo (192 patients) groups. Outcomes were progression to severe/critical COVID‐19, a daily symptom score based on 11 pre‐defined symptoms, time to symptom resolution, a negative reverse transcription polymerase chain reaction, an EQ‐5D‐5L quality of life (QOL) score, and serious adverse events. Only one patient (in the placebo group) progressed to severe COVID‐19, thus we could not conclude the effect of Kovir on the prevention of disease progression. Kovir significantly reduced time to symptom resolution (median: 7 vs. 11 days, hazard ratio [95% confidence interval]: 2.03 [1.66–2.48]) compared to placebo. Kovir also increased the QOL score on days 7 and 14. No safety concerns were observed. To conclude, Kovir is safe and facilitates symptom relief for non‐severe COVID‐19 patients. We advocate using Kovir in the early phase of COVID‐19 for non‐severe adult patients.

show abstract

Section: Discussionmentioning

confidence: 94%

Section: Introductionmentioning

confidence: 99%